Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novartis AG (NVS) vs Plby Group Inc (PLBY) Price & Performance

Novartis AGTrade
Plby Group IncTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Plby Group Inc — how do they compare? Novartis AG trades at $152.54 (market cap $295.37B), while Plby Group Inc trades at $1.27 (market cap $162.94M). The key difference: Novartis AG is far larger — about 1812.8× Plby Group Inc's market cap, and Novartis AG pays a 3.07% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.

NVSPLBY
Market Cap
$295.37B$162.94M
Sector
HealthConsumer Cyclical
52-Week High
$168.62$2.71
52-Week Low
$119.31$1.11
Enterprise Value
$336.69B$308.52M
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.

The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.

Plby Group Inc

PLBY trades at $1.28, up 8.47% in the last session, with a bullish technical signal from moving averages. The company shows improving fundamentals, with Q2 2026 revenue growth and a return to operating profitability, while net income margin remains slim at 0.23%. Recent news highlights inclusion in the Russell 2000 index and a share repurchase program.

The outlook is cautiously optimistic, supported by analyst consensus and positive cash flow trends, but high debt levels and inconsistent earnings history pose risks. Investment opportunity lies in brand licensing growth, while execution and competitive pressures are key watchpoints.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS

About Plby Group Inc

PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.

Read more on PLBY